Home › Funds › ARCH Venture Management, LLC › ERAS
ARCH Venture Management, LLC position in ERAS
ERASCA INC · Health Care
ARCH Venture Management, LLC reported holding 7,091,557 shares of ERAS (ERASCA INC) in its Q2 2026 13F filing — a position valued at US$129.9M, representing 11.81% of its reported portfolio and ranking #5 among its reported holdings. ARCH Venture Management, LLC has disclosed ERAS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARCH Venture Management, LLC's ERAS position evolved
ARCH Venture Management, LLC first disclosed a stake in ERAS in Q3 2023 at 11,055,554 shares (US$21.8M). The position peaked in Q2 2026 at 7,091,557 shares, worth US$129.9M. Across 12 filings, ARCH Venture Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 7,091,557 shares valued at US$129.9M. Notable position changes include a 36% trim in Q1 2026 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 11.06M | $21.78M | New |
| Q4 2023 | 11.06M | $23.55M | Hold |
| Q1 2024 | 11.06M | $22.77M | Hold |
| Q2 2024 | 11.06M | $26.09M | Hold |
| Q3 2024 | 11.06M | $30.18M | Hold |
| Q4 2024 | 11.06M | $27.75M | Hold |
| Q1 2025 | 11.06M | $15.15M | Hold |
| Q2 2025 | 11.06M | $14.10M | Hold |
| Q3 2025 | 11.06M | $24.10M | Hold |
| Q4 2025 | 11.06M | $41.13M | Hold |
| Q1 2026 | 7.09M | $114.74M | Reduce |
| Q2 2026 | 7.09M | $129.92M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 78 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 11.40M sh · $208.81M · Q2 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.25M sh · $96.18M · Q2 2026
- Vivo Capital, LLC 4.13M sh · $75.61M · Q2 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- Soleus Capital Management, L.P. 2.70M sh · $49.46M · Q2 2026
- SAMLYN CAPITAL, LLC 2.26M sh · $41.35M · Q2 2026
More on ARCH Venture Management, LLC
FAQ
How long has ARCH Venture Management, LLC held ERAS?
ARCH Venture Management, LLC has disclosed ERAS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ARCH Venture Management, LLC's current position in ERAS?
As of Q2 2026, ARCH Venture Management, LLC holds 7.09M shares of ERAS (ERASCA INC), valued at $129.92M, representing 11.81% of its reported portfolio and ranking #5.
Has ARCH Venture Management, LLC been buying or selling ERAS?
In the latest 13F filing (Q2 2026), ARCH Venture Management, LLC held unchanged its position in ERAS. The position peaked in Q2 2026 at 7.09M shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.